28 May 2024
Annual General Meeting of Ipsen S.A. held on 28 May 2024
27 May 2022
ASCO 2022: New Cabometyx® data show encouraging results in monotherapy and in combination across different…
08 February 2024
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
18 November 2024
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in…
13 February 2023
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line…
Explore more press releases
Topics
Period
recent search
Showing: 1 – 05 of 158 Press Releases
29 January 2026
29 January 2026
Ipsen nominates Peter Guenter to its Board of Directors
PARIS, FRANCE, 29 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026, further to the vacancy of Mr. Henri Beaufour’s position.
27 January 2026
27 January 2026
Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team
PARIS, FRANCE, 27 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Pierrick Lefranc will be appointed as Executive Vice President (EVP) and member of the Executive Leadership Team (ELT), as of 1 April 2026. Pierrick will succeed Aidan…
21 January 2026
21 January 2026
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
PARIS, FRANCE, 21 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced that the Arbitral Tribunal of the International Chamber of Commerce (ICC) has issued a final decision in favor of Ipsen, dismissing the claim initiated by Galderma in the arbitration…
14 January 2026
14 January 2026
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
PARIS, FRANCE, 14 JANUARY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today the presentation of 14 across multiple neurological conditions at the TOXINS 2026 conference (14-17 January) in Madrid, Spain. Data presented highlighted the depth and diversity of evidence…
13 January 2026
13 January 2026
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
PARIS, FRANCE, 13 JANUARY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for IPN60340 in combination with venetoclax and azacitidine (Ven-Aza) in first line unfit…
